KEYNOTE is the name given to the global clinical trial programme evaluating pembrolizumab. Spanning over 30 tumour types and involving tens of thousands of patients across multiple continents, it has produced some of the most significant results in modern oncology. Here is what the data tells us.
KEYNOTE-024: Lung cancer with high PD-L1 expression
Published in 2016 and updated with long-term follow-up data, KEYNOTE-024 compared pembrolizumab to platinum-based chemotherapy as the first treatment given to patients with non-small cell lung cancer (NSCLC) and a Tumour Proportion Score (TPS) of 50% or higher. This was a population that had historically received chemotherapy as the only available option.
The results were striking. Pembrolizumab produced a median progression-free survival of 10.3 months, compared to 6.0 months with chemotherapy. At five-year follow-up, approximately 31% of pembrolizumab patients remained alive versus 16% in the chemotherapy arm. These numbers represented a transformation in a disease where five-year survival had previously been uncommon.
KEYNOTE-001 and KEYNOTE-006: Melanoma
In advanced melanoma - a disease with historically very poor prognosis - pembrolizumab produced landmark survival data. KEYNOTE-001, which enrolled both previously treated and treatment-naive patients, reported that approximately 34% of patients were alive at five years. For patients who had not previously received treatment, the five-year survival rate was around 41%.
To put this in context: historically, five-year survival in advanced melanoma was approximately 5% with older treatments. The improvement represented by these figures is one of the most dramatic documented in modern oncology. KEYNOTE-006 confirmed pembrolizumab's superiority over ipilimumab, an earlier checkpoint inhibitor, across response rate, progression-free survival, and tolerability.
KEYNOTE-048: Head and neck cancer
In recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), KEYNOTE-048 compared pembrolizumab-based regimens to the previous standard of care (cetuximab plus chemotherapy). For patients with a Combined Positive Score (CPS) of 20 or higher, pembrolizumab monotherapy produced a median overall survival of 14.9 months versus 10.7 months with the control regimen. Pembrolizumab is now a standard first-line option for eligible HNSCC patients.
What the data means in practice
Clinical trial data reflects outcomes in defined patient populations, not individual predictions. Individual responses vary substantially based on PD-L1 expression, cancer type, stage, performance status, and other biological factors. Some patients in the KEYNOTE programme achieved sustained remissions lasting many years; others did not respond or had limited benefit.
What the KEYNOTE programme consistently shows is a pattern unique to immunotherapy: a subset of patients achieves responses that prove unusually durable - persisting beyond treatment cessation in some cases, with five-year survival outcomes that would have seemed extraordinary a decade ago. For eligible patients, this is what makes pembrolizumab worth considering seriously.
Interpreting what this evidence means for any individual requires a qualified oncologist who can assess your specific cancer, biomarkers, and clinical situation.
Could you benefit from pembrolizumab?
Our eligibility check is reviewed by a qualified oncologist within 24 hours. It is the right starting point for understanding whether the evidence applies to your situation.
Check your eligibility